BioStock: Last patient dosed in Respiratorius’ PK study with VAL001

Respiratorius finished June with good news announcing that the last patient had been dosed in the pharmacokinetic study with VAL001. The drug candidate against diffuse large B-cell lymphoma , VAL001, has undergone a clinical study to evaluate the tailor-made release profile before a phase III study can be initiated. BioStock took the opportunity to ask CEO Johan Drott a few of questions.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/last-patient-dosed-in-respiratorius-pk-study-with-val001/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se